SCHEMBL3016804

SCHEMBL3016804

Cc1ccccc1-c1csc(N2CCC(S(=O)(=O)c3ccc(Cl)c(Cl)c3)CC2)n1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.42
RAB9A P51151 2/20 0.42
NPC1 O15118 1/20 0.42
AR P10275 5/20 0.41
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
MAPK1 P28482 1/20 0.39
ALDH1A1 P00352 2/20 0.39
CYP1A2 P05177 1/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
CYP2C9 P11712 1/20 0.39
HPGD P15428 1/20 0.39
CYP2C19 P33261 1/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
EIF4E P06730 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3012330 0.93 AR (0.40) SMN1; SMN2RAB9ANPC1ARKMT2A
SCHEMBL3019555 0.92 SMN1; SMN2 (0.46) SMN1; SMN2RAB9ANPC1ARKMT2A
SCHEMBL3008446 0.90 AR (0.55) SMN1; SMN2RAB9ANPC1ARKMT2A
SCHEMBL3008975 0.89 SMN1; SMN2 (0.43) SMN1; SMN2RAB9ANPC1ARKMT2A
SCHEMBL15671697 0.89 AR (0.44) SMN1; SMN2RAB9ANPC1ARKMT2A
SCHEMBL3011699 0.89 SMN1; SMN2 (0.44) SMN1; SMN2RAB9ANPC1ARKMT2A
SCHEMBL3012581 0.89 SMN1; SMN2 (0.44) SMN1; SMN2RAB9ANPC1ARKMT2A
SCHEMBL3016323 0.89 RAB9A (0.47) SMN1; SMN2RAB9ANPC1ARKMT2A
SCHEMBL3012677 0.88 AR (0.46) SMN1; SMN2RAB9ANPC1ARKMT2A
SCHEMBL3009928 0.87 GBA1 (0.48) SMN1; SMN2RAB9ANPC1ARKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885RAB9A 2943/4885NPC1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.